Clinical trials
Transplantation clinical trials
Below are recruiting transplantation clinical trials, each written for real people, not researchers. We’re tracking 1,489 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06939751Recruiting
Testing microRNA levels to personalize heart transplant care
This trial is studying whether a blood test that measures small molecules called microRNAs can help doctors personalize the medicines used to prevent rejection after a heart transplant. If you qualify, you would help researchers learn how to better match immunosuppression to each patient's needs.
Los Angeles, CaliforniaAges 18–99 - NCT06532890Recruiting
Using microRNAs to personalize heart transplant medicines in children
This study is looking at heart transplant children (up to age 18) to see if measuring tiny molecules called microRNAs in the blood can help doctors personalize anti-rejection medicines. It aims to improve how we prevent rejection while reducing side effects.
Aurora, ColoradoAges Up to 18 years - NCT05470491RecruitingPhase 1/Phase 2
Haploidentical bone marrow transplant with GVHD prevention drugs
This trial tests a reduced-intensity bone marrow transplant from a related donor (haploidentical), using medicines to help prevent a serious complication called GVHD. It is for people with certain blood cancers and aims to improve outcomes by balancing transplant benefit with lower treatment intensity.
Bethesda, MarylandAges 12–120 - NCT07605416RecruitingPhase 2
Testing New Drug Combination for Plasma Cell Leukemia
This study tests a new combination of medicines to treat plasma cell leukemia, a rare blood cancer. The trial aims to help patients newly diagnosed with this condition by using drugs that work against cancer cells in different ways.
Chicago, IllinoisAges 18–80 - NCT06918990RecruitingPhase 1
CarBel for antibody-mediated rejection after kidney transplant
This study tests a new drug called CarBel to treat antibody-mediated rejection in kidney transplant patients. The goal is to see if it can help stop the rejection and protect your new kidney.
Birmingham, AlabamaAges 18–75 - NCT07495631Recruiting
Chemo + venetoclax + immunotherapy for adult ALL
This trial combines a kid-inspired chemotherapy backbone with a targeted pill (venetoclax) and immunotherapy (special antibodies) to treat adults with Ph-negative acute lymphoblastic leukemia (ALL). The goal is to use a more effective, less toxic approach developed for children.
Tianjin, Tianjin MunicipalityAges 14–60 - NCT06504225Recruiting
Long-term follow-up for EVEROLD study patients
This trial follows patients who completed the EVEROLD study to collect long-term health data. It is an observational study that does not test a new treatment.
AmiensAges 18 years+ - NCT06342557Recruiting
App-Based Health Diary for Young Liver Transplant Patients
This study uses an app (ePRO Diary) to track your health after a liver transplant or while waiting for one. It’s designed for young people between 14 and 20 years old who are moving from pediatric to adult care.
Bergamo, MILANOAges 14–20 - NCT05632380RecruitingPhase 1/Phase 2
Stem cell transplant with CAR-T therapy for high-risk myeloma
This study combines a stem cell transplant with a special immune therapy (CAR-T) to treat multiple myeloma that is very aggressive and has not responded well to initial treatments. The goal is to see if this combination can better control the cancer.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07490288Recruiting
Venetoclax, azacitidine, and mitoxantrone for new AML
This trial tests a combination of three drugs (venetoclax, azacitidine, and liposomal mitoxantrone) as a first treatment for people newly diagnosed with acute myeloid leukemia (AML). The goal is to see if this combination works better than standard care.
Tianjin, Tianjin MunicipalityAges 14–100 - NCT07409454RecruitingPhase 2
Post-transplant treatment for multiple myeloma with a bispecific antibody
This trial tests a drug that helps your immune system target and kill myeloma cells after a stem cell transplant. It is for people with newly diagnosed multiple myeloma who still have minimal residual disease (small amounts of cancer) after their first transplant.
TianjinAges 18 years+ - NCT07335523Recruiting
Testing for poor digestion in Alagille syndrome after liver transplant
This study looks for signs of poor digestion after a liver transplant in people with Alagille syndrome. You collect stool samples for 3 days while on a high-fat diet to see if your pancreas is making enough enzymes.
Aurora, ColoradoAges 7–50 - NCT06371924Recruiting
Machine perfusion for livers from donation after circulatory death
This study tests a new way to preserve donated livers (called machine perfusion) after they are recovered from donors who died from circulatory causes. It aims to see if this method helps the liver work better before transplant.
BirminghamAges 18 years+ - NCT05940857Recruiting
Liver transplant registry using a special machine before surgery
This is a registry that collects information about liver transplant recipients. It helps researchers understand outcomes related to a specific liver “perfusion” process used around the time of transplant.
Birmingham, AlabamaAges Any age - NCT05327478Recruiting
Compare treatments for controlled donation after circulatory death
This trial compares different care approaches for adult donors in a specific type of controlled donation after the heart stops. It aims to find which approach best supports organ/tissue use after donation.
Rotterdam, South HollandAges 50–75 - NCT05011422RecruitingPhase 1
Haploidentical stem cell transplant for high-risk leukemia in children
This early-phase study tests a transplant using a “partially matched” (haploidentical) donor’s stem cells, with extra lab steps to reduce certain immune cells. It is designed for children with high-risk blood cancers to lower relapse risk and improve outcomes.
St Louis, MissouriAges Up to 30 years - NCT04373473RecruitingPhase 2
Oral stool treatment to prevent ulcerative colitis flare-ups
This study tests whether taking freeze-dried (lyophilized) donor stool material by mouth can help prevent ulcerative colitis from coming back or causing intestinal inflammation. Participants are in remission and stay on their usual treatment while receiving the study product.
Houston, TexasAges 18 years+ - NCT02438904Recruiting
Get help selecting stem cells after poor transplant recovery
This trial offers a specialized device to help choose certain stem cells after a transplant when graft function is poor or not working. It may help improve how well the transplant takes and functions in your body.
Houston, TexasAges Any age - NCT01656603RecruitingPhase 2
Safety study of unlicensed cord blood for unrelated transplants
This trial studies whether unlicensed (not FDA-approved) cord blood units made by a specific program are safe to use for unrelated transplants. It may help doctors confirm safe ways to use these units for people who need a transplant for blood-forming system disorders.
Birmingham, AlabamaAges Any age - NCT01293214Recruiting
Transplanting new tissue for multiple amputated limbs
This trial studies whether a transplant of tissue and blood vessels can improve function after limb amputations when prosthetic devices have not worked. It requires long-term medicines to prevent rejection, close follow-up, and intensive rehabilitation.
Boston, MassachusettsAges 18–60 - NCT06483100RecruitingPhase 2
Elranatamab after stem cell transplant for multiple myeloma
This trial tests a drug called elranatamab to keep multiple myeloma from coming back after an autologous stem cell transplant. It is for people who still have small amounts of cancer cells detectable after transplant.
St Louis, MissouriAges 18 years+ - NCT07438067RecruitingPhase 1
EBV-targeted cell therapy after stem cell transplant
This trial tests a special immune cell therapy (EBV-AST) for people who have high levels of Epstein-Barr virus (EBV) in their blood after a stem cell transplant. The goal is to see if it can safely control the virus and prevent related complications.
BeijingAges 18–75 - NCT07444489Enrolling by invitationPhase 3
Long-term safety of felzartamab for kidney transplant rejection
This study checks the long-term safety of felzartamab for people who have had a kidney transplant and are dealing with antibody-mediated rejection or signs of inflammation in the kidney. It's for those who were already in a previous study and took at least one dose of felzartamab.
Los Angeles, CaliforniaAges 18–75 - NCT06936566RecruitingPhase 2
Ruxolitinib for graft-versus-host disease after transplant
This trial tests a drug called ruxolitinib for treating acute graft-versus-host disease (aGVHD), a common complication after a stem cell transplant. It may help control the immune reaction without using high doses of steroids.
Duarte, CaliforniaAges 18 years+
Hear when a new Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for transplantation?
- Yes. Clin2 currently lists 1,489 recruiting transplantation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a transplantation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a transplantation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.